OnKure Therapeutics Inc. (OKUR)
| Bid | 2.9 |
| Market Cap | 40.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.56M |
| EPS (ttm) | -15.28 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -1.61 |
| Analyst | Buy |
| Ask | 2.98 |
| Volume | 3,661 |
| Avg. Volume (20D) | 59,193 |
| Open | 3.08 |
| Previous Close | 2.95 |
| Day's Range | 2.96 - 3.08 |
| 52-Week Range | 2.57 - 20.00 |
| Beta | 0.35 |
About OKUR
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado....
Analyst Forecast
According to 4 analyst ratings, the average rating for OKUR stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 978.48% from the latest price.
Stock Forecasts
5 months ago · seekingalpha.com
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And BeyondInitial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...